Many non-small cell lung cancer (NSCLC) patients who receive EGFR-tyrosine kinase inhibitors (TKIs) like erlotinib (Tarceva) and gefitinib (Iressa) develop drug resistance. Some of these patients may also have a small number of metastases (oligometastatic disease), which can be destroyed with local therapy. Local therapy methods include surgical removal, radiation, or electrical current produced by high-frequency radio waves (radiofrequency ablation). A recent study explored the use of local therapy, followed by renewed treatment with EGFR-TKIs, in patients with oligometastatic NSCLC who had become resistant to EGFR-TKIs. The treatment was well tolerated and effective, especially for patients in whom local therapy had removed all known tumors.